Effects of PCSK9 inhibitor evolocumab on preventing early neurological deterioration in acute ischemic stroke patients with or without large artery atherosclerosis: a subgroup analysis of a randomized trial.

Jiahui Liu et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedas reported · 272 people · 2025

Not counted

Probably increased cardiovascular events

+39%+18% to +65%

Bigger than 7 in 10 for cardiovascular events

As reported

RR 1.39, 95% CI 1.18–1.65

Range includes no effect

No clear effect on cardiovascular events

+16%−5% to +42%

Bigger than 3 in 10 for cardiovascular events

As reported

RR 1.16, 95% CI 0.95–1.42

Two numbers in the abstract

the abstract, start to end

… the LAA group (81.7% versus 61.3%; RR, 1.39; 95% CI, 1.18 to 1.65; p < 0.001), but not in the SVO subtype (86.0% versus 74.4%; RR, 1.16; 95% CI, 0.95 to 1.42; …

← favours treatmentfavours comparator →

could be chance

Cardiovascular events

RR 1.391.18–1.65

Cardiovascular events

RR 1.160.95–1.42

StatinsPCSK9 inhibitorsCardiovascular events

1 / 3

3 papers cite it

2025

2026

this papercites it

The trial

NCT07466251phase 41,212 enrolled2026